A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has […]
Subscribe for instant access to all Lawyerly content. Already a subscriber? Login here. Want to test drive Lawyerly? Contact us to take a free trial.
